Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25512062 | 0.92 | TMIGD3 (0.40) | TMIGD3ADORA3ADORA1ADORA2APOLB | |
| SCHEMBL2114275 | 0.90 | POLB (0.34) | TMIGD3ADORA2APOLBHSP90AA1HSP90AB1 | |
| SCHEMBL7599198 | 0.88 | TMIGD3 (0.36) | TMIGD3ADORA3ADORA1ADORA2APOLB | |
| SCHEMBL7651302 | 0.88 | TMIGD3 (0.36) | TMIGD3ADORA3ADORA1ADORA2APOLB | |
| SCHEMBL332975 | 0.86 | POLB (0.51) | TMIGD3ADORA3POLBHSP90AA1HSP90AB1 | |
| SCHEMBL7533550 | 0.86 | POLB (0.51) | TMIGD3ADORA3POLBHSP90AA1HSP90AB1 | |
| SCHEMBL8607542 | 0.84 | POLB (0.49) | ADORA3POLBHSP90AA1HSP90AB1ABL1 | |
| SCHEMBL25512274 | 0.84 | POLB (0.42) | TMIGD3POLBABL1RIN1 | |
| SCHEMBL10821859 | 0.84 | TMIGD3 (0.34) | TMIGD3ADORA3ADORA1ADORA2APOLB | |
| SCHEMBL7599000 | 0.83 | TMIGD3 (0.33) | TMIGD3ADORA3ADORA1ADORA2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158770-B2 | Content dependent inhibitors of cytidine deaminases and uses thereof | UNIVERSITY OF ROCHESTER (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-16 | — | — | US | disclosed |
| US-20040014699-A1 | Antisense modulation of PTPRM expression | ISIS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-20030224511-A1 | Oligonucleotide for preventing cysteine protease expression (CAPTHESIN Z) and treatment of viral, infectious and tumor diseases | ISIS PHARMACEUTICALS INC. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | DCTD, CDA, ADA | TMIGD3 2598/4885ADORA3 974/4885ADORA1 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.